Gastroesophageal reflux disease: Natural history and long-term medical and surgical outcomes

Clinical Cornerstone

Volumn 5, Issue 4, 2003, Pages 51-57

  Tutuian, Radu ^a   Castell, Donald O ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGINIC ACID; ANTACID AGENT; BACLOFEN; BETHANECHOL; CALCIUM CARBONATE; CIMETIDINE; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METOCLOPRAMIDE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PRISOLEC; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SUCRALFATE; TEGASEROD;

ANTIREFLUX OPERATION; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ESOPHAGOSCOPY; ESOPHAGUS CARCINOMA; ESOPHAGUS MANOMETRY; ESOPHAGUS PH; ESOPHAGUS STRICTURE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; OUTCOMES RESEARCH; PATIENT SELECTION; SIDE EFFECT; STOMACH ACID; STOMACH EMPTYING; TREATMENT OUTCOME;

EID: 1842861998     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(03)90099-8     Document Type: Article

References (27)

1. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. Gastroenterology. 2002;122:1500-1511.
2. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: A population based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
3. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: Incidence and precipitating factors. Am J Dig Dis. 1976;21:953-956.
4. Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Baillieres Best Pract Res Clin Gastroenterol. 2000;14:743-757.
5. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol. 1983;78:257-260.
6. Marks RD, Richter JE. Peptic strictures of the esophagus. Am J Gastroenterol. 1993;88: 1160-1173.
7. Spechler SJ, Goyal RK. The columnar lined esophagus, intestinal metaplasia, and Norman Barrett. Gastroenterology. 1996;110:614-621.
8. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
9. Robinson M. Medical management of gastroesophageal reflux disease. In: Castell DO, Richter JE, eds. The Esophagus. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:447-462.
10. Pappa KA, Gooch WM, Buaron K, et al. Low-dose ranitidine for the relief of heartburn. Aliment Pharmacol Ther. 1999;13:459-465.
11. Xue S, Katz PO, Banerjee P, et al. Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors. Aliment Pharmacol Ther. 2001;15:1351-1356.
12. DeVault KR. Overview of medical therapy for gastroesophageal reflux disease. Gastroenterol Clin North Am. 1999;28:831-846.
13. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology. 2000;118:661-669.
14. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994;35:590-598.
15. Sifrim D, Holloway R, Silny J, et al. Acid, nonacid, and gas reflux in patients with gastroesophageal reflux disease during ambulatory 24-hour pH-impedance recordings. Gastroenterology. 2001; 120:1588-1598.
16. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: Effect of omeprazole. Gastroenterology. 2001;120:1599-1606.
17. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg. 2001;192:172-179.
18. Branton SA, Hinder RA, Floch NR, et al. Surgical treatment of gastroesophageal reflux disease. In: Castell DO, Richter JE, eds. The Esophagus. 3rd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:511-525.
19. Campos GM, Peters JH, DeMeester TR, et al. Multivariate analysis of factors predicting outcome after laparoscopic Nissen fundoplication. J Gastrointest Surg. 1999;3:292-300.
20. Fibbe C, Layer P, Keller J, et al. Esophageal motility in reflux disease before and after fundoplication: A prospective, randomized, clinical, and manometric study. Gastroenterology. 2001;121:5-14.
21. Tutuian R, Vela MF, Balaji N, et al. Esophageal function testing using combined multichannel intraluminal impedance and manometry. Multicenter study of healthy volunteers. Clin Gastroenterol Hepatol. 2003;1:174-182.
22. Tutuian R, Castell DO. Clarification of the esophageal function defect in patients with manometric ineffective esophageal motility. Clin Gastroenterol Hepatol. In press.
23. Kauer WK, Peters JH, DeMeester TR, et al. A tailored approach to antireflux surgery. J Thorac Cardiovasc Surg. 1995;110:141-146.
24. Hagedorn C, Lonroth H, Rydberg L, et al. Long-term efficacy of total (Nissen-Rossetti) and posterior partial (Toupet) fundoplication: Results of a randomized clinical trial. J Gastrointest Surg. 2002; 6:540-545.
25. Zornig C, Strate U, Fibbe C, et al. Nissen vs Toupet laparoscopic fundoplication. Surg Endosc. 2002;6:758-766.
26. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: Follow-up of a randomized controlled trial. JAMA. 2001;285:2331-2338.
27. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med. 2003;114:1-5.